Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 2/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10188513 | 0.85 | ALDH1A1 (0.36) | ALDH1A1HSD17B10USP2TSHRLMNA | |
| SCHEMBL13601049 | 0.84 | LMNA (0.47) | ALDH1A1LMNAHPGDHTTKMT2A | |
| SCHEMBL2601033 | 0.84 | MAOA (0.32) | CYP2C19PARP1 | |
| SCHEMBL19157805 | 0.81 | KDM4E (0.39) | ALDH1A1HSD17B10USP2TSHRLMNA | |
| SCHEMBL20015194 | 0.81 | LMNA (0.41) | ALDH1A1HSD17B10USP2TSHRLMNA | |
| SCHEMBL21120816 | 0.80 | ALDH1A1 (0.38) | ALDH1A1HSD17B10USP2TSHRLMNA | |
| SCHEMBL18473858 | 0.80 | ALDH1A1 (0.38) | ALDH1A1HSD17B10USP2TSHRLMNA | |
| SCHEMBL22605391 | 0.79 | LMNA (0.46) | ALDH1A1LMNAKMT2ACYP2C19 | |
| SCHEMBL20015192 | 0.79 | ALDH1A1 (0.42) | ALDH1A1HSD17B10USP2TSHRLMNA | |
| SCHEMBL19334679 | 0.79 | LMNA (0.39) | ALDH1A1HSD17B10USP2TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807648-B2 | Process for preparing substituted polycyclic pyridone derivative and crystal thereof | SHIONOGI & CO., LTD. (JP) | 2023-11-07 | — | — | US | disclosed |
| US-11807648-B2 | Process for preparing substituted polycyclic pyridone derivative and crystal thereof | SHIONOGI & CO., LTD. (JP) | 2023-11-07 | — | — | US | disclosed |
| US-20210230187-A1 | PROCESS FOR PREPARING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVE AND CRYSTAL THEREOF | SHIONOGI & CO., LTD. (JP) | 2021-07-29 | — | — | US | disclosed |
| US-10202379-B2 | Substituted polycyclic carbamoyl pyridone derivative prodrug | SHIONOGI & CO., LTD. (JP) | 2019-02-12 | — | — | US | disclosed |
| EP-2620436-B1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO (JP) | 2018-05-09 | — | — | EP | disclosed |
| EP-2444400-B1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | SHIONOGI & CO (JP) | 2018-03-28 | — | — | EP | disclosed |
| US-20170349587-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
| US-9815835-B2 | Substituted polycyclic carbamolypyridone derivative | SHIONOGI & CO., LTD. (JP) | 2017-11-14 | — | — | US | disclosed |
| US-9758515-B2 | Substituted polycyclic carbamoyl pyridone derivative prodrug | SHIONOGI & CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230187-A1 | PROCESS FOR PREPARING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVE AND CRYSTAL THEREOF | REN, C5, PDXK | ALDH1A1 3226/4885HSD17B10 1057/4885USP2 3848/4885 |
| US-11807648-B2 | Process for preparing substituted polycyclic pyridone derivative and crystal thereof | REN, C5, PDXK | ALDH1A1 3226/4885HSD17B10 1057/4885USP2 3848/4885 |
| US-20170349587-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | PREP, UNG, DPP4 | ALDH1A1 1564/4885HSD17B10 1241/4885USP2 1225/4885 |
| US-10202379-B2 | Substituted polycyclic carbamoyl pyridone derivative prodrug | PREP, UNG, DPP4 | ALDH1A1 1564/4885HSD17B10 1241/4885USP2 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.